Results 1 to 10 of about 905 (194)

Cognitive, neuropsychiatric and neurological alterations in mastocytosis: A systematic review [PDF]

open access: yesClinical and Translational Allergy, 2023
Background Mastocytosis manifests with multisystemic symptoms, often involving the nervous system. Numerous cognitive, neuropsychiatric and neurological alterations have been reported in multiple observational studies.
Elena Sagües‐Sesé   +2 more
doaj   +3 more sources

Mastocytosis presenting with mast cell‐mediator release‐associated symptoms elicited by cyclo oxygenase inhibitors: prevalence, clinical, and laboratory features [PDF]

open access: yesClinical and Translational Allergy, 2022
Background Nonsteroidal anti‐inflammatory drugs (NSAIDs) are frequently avoided in mastocytosis, because of a potential increased risk for drug hypersensitivity reactions (DHRs) due to inhibition of cyclo‐oxygenase (COX), subsequent depletion of ...
Tiago Azenha Rama   +9 more
doaj   +3 more sources

Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal [PDF]

open access: yesHemaSphere, 2021
Mastocytosis is a hematologic neoplasm characterized by expansion and focal accumulation of neoplastic mast cells (MC) in diverse organs, including the skin, bone marrow (BM), spleen, liver, and gastrointestinal tract.
Peter Valent   +39 more
doaj   +3 more sources

Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap [PDF]

open access: yesFrontiers in Pharmacology, 2020
Systemic mastocytosis is a rare and heterogeneous disease characterized by mast cell proliferation and activation. KIT is a transmembrane tyrosine kinase which plays a key role in mast cell growth, differentiation and survival. After interaction with its
Miguel Piris-Villaespesa   +1 more
doaj   +2 more sources

Whole-Exome Sequencing Reveals Recurrent but Heterogeneous Mutational Profiles in Sporadic WHO Grade 1 Meningiomas [PDF]

open access: yesFrontiers in Oncology, 2021
Human WHO grade 1 meningiomas are generally considered benign tumors; despite this, they account for ≈50% of all recurrent meningiomas. Currently, limited data exist about the mutational profiles of grade 1 meningiomas and patient outcome.
María González-Tablas   +28 more
doaj   +2 more sources

Insights in Anaphylaxis and Clonal Mast Cell Disorders [PDF]

open access: yesFrontiers in Immunology, 2017
The prevalence of anaphylaxis among patients with clonal mast cell disorders (MCD) is clearly higher comparing to the general population. Due to a lower frequency of symptoms outside of acute episodes, clonal MCD in the absence of skin lesions might ...
David González-de-Olano   +1 more
doaj   +2 more sources

Mastocitosis cutánea maculopapular infantil: reporte de un caso

open access: yesRevista Médica Clínica Las Condes, 2019
Resumen: Objetivo: Reportar un caso de mastocitosis cutánea maculopapular de inicio en la infancia y realizar una revisión bibliográfica con énfasis en el diagnóstico, estudio, pronóstico y tratamiento.
Renatta de Grazia   +3 more
doaj   +3 more sources

Mastocytosis

open access: yesRevista Alergia México, 2015
Mastocytosis is one of the eight subcategories of the myeloproliferative neoplasms of the classification of lymphoid and hematopoietic tissues’ tumors of 2008 of World Health Organization; it is an heterogeneous group of myeloproliferative diseases ...
Sandra Nora González-Díaz   +3 more
doaj   +3 more sources

Anaphylaxis events in the PIONEER study of avapritinib in indolent systemic mastocytosis [PDF]

open access: yesWorld Allergy Organization Journal
Background: Patients with indolent systemic mastocytosis (ISM), a clonal mast cell disease primarily driven by the KIT D816V mutation, often have lifelong debilitating symptoms.
Thanai Pongdee, MD   +17 more
doaj   +2 more sources

Pregnancy and Delivery in Patients with Mastocytosis Treated at the Polish Center of the European Competence Network on Mastocytosis (ECNM). [PDF]

open access: yesPLoS ONE, 2016
OBJECTIVE:To present current guidelines regarding treatment of mastocytosis in pregnancy on the example of observed patients. DESIGN:Case control national study. SETTING:Polish Center of the European Competence Network on Mastocytosis (ECNM).
Katarzyna Ciach   +9 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy